Use of Pfizer Inc.’s COVID-19 oral antiviral treatment Paxlovid jumped 315 percent over the past four weeks, the U.S. Department of Health and Human Services said on May 17, as health officials try to address unexpectedly light demand.

The United States will allow baby formula imports from foreign makers that do not usually sell their products here, the Food and Drug Administration said on May 16, as it tries to ease a nationwide shortage that has left parents scrambling to feed their babies.

The White House is preparing for a scenario in which Congress fails to approve President Joe Biden’s request for additional COVID funds by reviewing old contracts to see if there is any money it can “claw back,” the president’s top COVID adviser said on May 12.

President Joe Biden on May 12 commemorated the death of 1 million people in the United States from COVID-19, marking what he called “a tragic milestone” and urging Americans to “remain vigilant” amid the ongoing pandemic.

U.S. President Joe Biden’s administration is aiming to expand access to COVID-19 oral antiviral treatments like Pfizer Inc.’s Paxlovid by doubling the number of locations at which they are available, the White House said on April 26.

A second Global COVID-19 Summit will be held virtually during May for countries to discuss efforts to end the pandemic and prepare for future health threats, according to a joint statement on April 18.

The Biden administration on Wednesday launched a new website to provide a clearinghouse of information on COVID-19 as part of a continuing effort to prepare Americans to live with the coronavirus.

While Moderna and Pfizer-BioNTech have submitted Emergency Use Authorization (EUA) requests for their COVID-19 vaccines, the data so far suggest the benefits of a fourth shot may be modest.

U.S. President Joe Biden on March 17 named public health expert Dr. Ashish Jha to replace White House COVID-19 coordinator Jeff Zients, who will leave his post in April, as the administration prepares for new COVID-19 variants and infection surges that could hit the country.

The U.S. government will run out of supplies of COVID-19 treatments known as monoclonal antibodies as soon as late May and will have to scale back plans to get more unless Congress provides more funding, the White House said on March 15.